StockData
Repligen Corp logo

Repligen Corp (RGEN) stock

RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30136% above fair value
$163.81−6.48 (-3.81%)

Close on Nov 20, 2026Market cap $10.47BP/E –Yield –

Repligen net income

Net income is the profit left for shareholders after every expense, interest and tax.

Repligen's net income for the twelve months ending Sep 30, 2026 was -$11.80M, down 779.2% year over year. For fiscal 2025 it was $48.89M. Over ten years it grew 18.0% a year on average. The highest annual figure on record is $185.96M in fiscal 2022.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$48.89M–
FY2024Dec 31, 2024-$25.51M-171.7%
FY2023Dec 31, 2023$35.60M-80.9%
FY2022Dec 31, 2022$185.96M+45.0%
FY2021Dec 31, 2021$128.29M+114.1%
FY2020Dec 31, 2020$59.93M+179.9%
FY2019Dec 31, 2019$21.41M+28.8%
FY2018Dec 31, 2018$16.62M-41.4%
FY2017Dec 31, 2017$28.35M+142.7%
FY2016Dec 31, 2016$11.68M+25.0%
FY2015Dec 31, 2015$9.35M+14.4%
FY2014Dec 31, 2014$8.17M-49.2%
FY2013Dec 31, 2013$16.09M–
FY2011Mar 31, 2011-$43.51K–
FY2010Mar 31, 2010-$4.06M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$38.43M-357.7%
Q2 FY2026Jun 30, 2026$5.01M-66.3%
Q1 FY2026Mar 31, 2026$8.33M+42.9%
Q4 FY2025Dec 31, 2025$13.29M–
Q3 FY2025Sep 30, 2025$14.91M–
Q2 FY2025Jun 30, 2025$14.87M+160.2%
Q1 FY2025Mar 31, 2025$5.83M+76.9%
Q4 FY2024Dec 31, 2024-$33.87M–
Q3 FY2024Sep 30, 2024-$654.00K-103.9%
Q2 FY2024Jun 30, 2024$5.71M-71.1%
Q1 FY2024Mar 31, 2024$3.30M-78.5%
Q4 FY2023Dec 31, 2023-$16.45M-133.8%
Q3 FY2023Sep 30, 2023$16.92M-58.1%
Q2 FY2023Jun 30, 2023$19.79M-60.3%
Q1 FY2023Mar 31, 2023$15.34M-67.3%
Q4 FY2022Dec 31, 2022$48.73M+67.4%
Q3 FY2022Sep 30, 2022$40.41M+20.6%
Q2 FY2022Jun 30, 2022$49.86M+37.6%
Q1 FY2022Mar 31, 2022$46.96M+59.5%
Q4 FY2021Dec 31, 2021$29.11M+47.8%
Q3 FY2021Sep 30, 2021$33.50M+130.2%
Q2 FY2021Jun 30, 2021$36.23M+128.4%
Q1 FY2021Mar 31, 2021$29.45M+200.1%
Q4 FY2020Dec 31, 2020$19.70M+446.6%
Q3 FY2020Sep 30, 2020$14.55M+777.2%
Q2 FY2020Jun 30, 2020$15.86M+95.9%
Q1 FY2020Mar 31, 2020$9.82M+21.9%
Q4 FY2019Dec 31, 2019$3.60M-36.1%
Q3 FY2019Sep 30, 2019$1.66M-65.4%
Q2 FY2019Jun 30, 2019$8.10M+195.7%
Q1 FY2019Mar 31, 2019$8.05M+133.6%
Q4 FY2018Dec 31, 2018$5.64M-53.7%
Q3 FY2018Sep 30, 2018$4.79M+2.7%
Q2 FY2018Jun 30, 2018$2.74M-67.6%
Q1 FY2018Mar 31, 2018$3.45M+12.4%
Q4 FY2017Dec 31, 2017$12.18M+142.2%
Q3 FY2017Sep 30, 2017$4.67M–
Q2 FY2017Jun 30, 2017$8.44M–
Q1 FY2017Mar 31, 2017$3.07M–
Q4 FY2016Dec 31, 2016$5.03M–

More Repligen figures

See a number that looks wrong?